Welcome to the e-CCO Library!

P315 Short-chain fatty acid profile in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Oliveira, L. Yukie Sassaki, A. Elisa Valencise Quagli, J. Ribeiro de Barros

Created: Thursday, 30 January 2020, 10:12 AM
P315: Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Michetti*1, L. Peyrin-Biroulet2, M. S. Silverberg3, E. Louis4, J. Weinman5, J. Sommer6, J. Petersson7, B. Pappalardo7, P. Nurwakagari8

Created: Friday, 22 February 2019, 9:49 AM
P315: Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Collins M.*1, Michot J.-M.2, Danlos F.-X.2, Champiat S.2, Mussini C.1, Soularue E.1, Mateus C.3, Loirat D.4, Buisson A.5, Rosa I.1,6, Lambotte O.1, Laghouati S.2, Voisin A.-L.2, Soria J.-C.2, Marabelle A.2, Robert C.2, Carbonnel F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P315: High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study
Year: 2022
Source: ECCO'22
Authors: Karki, C.(1);Sharpe, E.(2);Hantsbarger, G.(3);Lee, K.(4);Perovic, M.(5);Raven, L.(6);Sajak-Szczerba, M.(7);Silber, A.(2);Yoon, A.(8);Tozer, P.(9);
Created: Friday, 11 February 2022, 3:52 PM
P315: Molecular screening for Lynch syndrome in IBD colorectal cancer
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Anele1*, G. Worley1, D. Georgiou2, M. Moorghen1, O. Faiz1, A. Latchford1

Created: Thursday, 21 February 2019, 9:14 AM
P315: Population pharmacokinetics and pharmacodynamics of ozanimod in ulcerative colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Tatosian, D.(1);Shen, J.(1);Chen, L.(1);Lavigne, J.(2);Teuscher, N.(3);Harris, S.(1);Chitkara, D.(1);Tirucherai, G.S.(1);Marta, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P315: Systemic and tissue modulation of IL-23 pathway biomarkers in a Phase 2 study of risankizumab in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Salas*1, K. M. Grebe2, N. Powell3, J. Panés1, J. W. Davis4, F. Hong4, Y. Pang4, A. A. Suleiman5, K. Wallace4, B. G. Feagan6

Created: Friday, 22 February 2019, 9:41 AM
P315: The characteristics and severity of pediatric ulcerative proctitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Müller, K.(1)*;Dohos , D.(2);Imrei, M.(3);Gombos, E.(3);Szentannay , J.(3);Szabó, A.(3);Oberfrank, M.(4);Karoliny, A.(5);
Created: Friday, 14 July 2023, 11:05 AM
P316: A study on the impact of diagnosis on the level of exercise amongst patients with IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Schembri1, K. Gatt1*, K.H. Katsanos2, D.K. Christodoulou2, D. Balomenos2, K. Karmiris3, C. Pontas4, U. Kopylov5, I. Koutroubakis6, K. Foteinogiannopoulou6, A. Fábián7, T. Molnár7, D. Zammit1, P. Ellul1, G.J. Mantzaris4

Created: Thursday, 21 February 2019, 9:14 AM
P316: Human neutrophil elastase derived fragment of calprotectin (S100a9) is a serum biomarker (CPa9-HNE) for monitoring of anti-TNFα treatment response in Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Mortensen, J.(1);Karsdal, M.A.(1);Grønbæk, H.(2);Hvas, C.L.(2);Dige , A.(2);Bay-Jensen, A.C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P316: Inflammatory Bowel Disease and malignancy: What are the predictors of malignancy in Inflammatory Bowel Disease?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Istemihan, Z.(1)*;Çavuş, B.(1);Bardak, A.E.(2);Kırkoğlu, A.M.(2);Kızıltaş, C.(2);Silay, R.(2);Şenkal, İ.V.(1);İmanov, Z.(1);Nuriyev, K.(1);Rüstemzade, A.(1);Genç, S.(1);Güllüoğlu, M.(3);Çifcibaşı Örmeci, A.(1);Demir, K.(1);Beşışık, F.(1);Kaymakoğlu, S.(1);Akyüz, F.(1);
Created: Friday, 14 July 2023, 11:05 AM
P316: New approaches for IBD management based on text mining of digitalised medical reports and latent class modelling
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bergey F.*1, Saccenti E.2, Jonkers D.3, van den Heuvel T.3, Jeuring S.3, Pierik M.3, Martins dos Santos V.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P316: Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North
Year: 2022
Source: ECCO'22
Authors: Sands, B.E.(1);Dignass, A.(2);Irving, P.(3);Chiorean, M.(4);Long, M.(5);Eren, D.(6);Ahmad, H.A.(6);Osterman, M.T.(6);Petersen, A.(6);Elegbe, A.(6);Ritter, T.(7);Danese, S.(8);
Created: Friday, 11 February 2022, 3:52 PM
P316: Prognosis of patients with inflammatory bowel disease in clinical remission after de-escalation of infliximab maintenance therapy from 8 to 12 weeks
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. M. Vázquez-Morón, B. Benítez-Rodríguez*, H. Pallarés-Manrique, M. Ramos-Lora

Created: Friday, 22 February 2019, 9:49 AM
P316: Transanal minimal invasive proctectomy (TaMIP) for perineal Crohn’s disease; a multi-centre prospective cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Chandrasinghe*1,2,3, F. Di Candido4, J. Warusavitarne2,5, A. Spinelli4,6

Created: Friday, 22 February 2019, 9:41 AM
P317 Key features of bowel ultrasonography in managing inflammatory bowel disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Les, R. Iacob, R. Costache, L. Gheorghe, C. Gheorghe

Created: Thursday, 30 January 2020, 10:12 AM
P317: Characterisation of patients with delayed response to ustekinumab for Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. E. Sands*1, A. Oortwijn2, N. Rijnders2, J. Izanec3, C. Gasink3, D. Jacobstein4, O. J. Adedokun4, T. Ma4, L-L. Gao4, J-F. Colombel5, S. Targan6, S. Ghosh7, W. J. Sandborn8

Created: Friday, 22 February 2019, 9:41 AM
P317: Health care costs associated with standard inflammatory bowel disease care in Australia and opportunities to improve care: a tertiary centre study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Jackson*1, R. Ma1, A. Gorelik2, D. Con1, D. Liew2, P. De Cruz1

Created: Friday, 22 February 2019, 9:49 AM
P317: MaRIA score in the assessment of disease activity in patients with ileocolonic Crohn’s disease; the correlation between radiological, endoscopic, and clinical findings
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Crncevic Urek1*, J. Ćurić2, L. Prka3, D. Kardum3, M. Banić3

Created: Thursday, 21 February 2019, 9:14 AM